Table 3 Use of glucose-lowering drugs in Mexico categorized by cardiovascular disease and in the overall study population
Study population N = 820 | CVD status | Overall study population (n = 9823) | ||
|---|---|---|---|---|
CVD n = 302 | No CVD n = 518 | |||
Any glucose lowering drug | 88.5% | 86.8% | 89.6% | 96.6% |
Any glucose lowering drug with proven CV benefit* | 16.3% | 9.6% | 20.3% | 21.9% |
Oral glucose lowering drugs | ||||
Biguanide | 79.4% | 76.8% | 80.9% | 75.6% |
DPP-4 inhibitor | 21.6% | 16.2% | 24.7% | 29.2% |
Sulfonylurea | 26.3% | 27.8% | 25.5% | 21.6% |
SGLT-2 inhibitor | 15.5% | 9.6% | 18.9% | 16.0% |
Alpha glucosidase inhibitor | 1.3% | 1.3% | 1.4% | 5.3% |
Thiazolidinedione | 5.2% | 5% | 5.4% | 3.8% |
Glinide | 0 | 0 | 0 | 3.3% |
Others | 0 | 0 | 0 | 0.3% |
Insulin | 36.1% | 39.1% | 34.4% | 37.7% |
GLP-1 receptor agonist (arGLP-1) | 3.9% | 1.0% | 5.6% | 10.1% |
Monotherapy | 32.3% | 36.8% | 29.7% | 30.0% |
Dual therapy† | 46.5% | 45.7% | 46.9% | 36.3% |
Triple therapy† | 15.9% | 14.2% | 16.8% | 22.3% |
Treatment with ≥ 4 glucose lowering drugs | 4% | 1.3% | 5.6% | 8.0% |